failed to attain significancep = 0.0698
Even though the study failed to attain significance for the primary endpoint (mean rank of 56.6 vs. 68.3, p = 0.0698), the pre-specified secondary outcomes (changes in QMG and MGQOL-15 scores and the responder analysis for MG-ADL and QMG) were significantly better in the Eculizumab group starting from week 1 and sustained through week 26, and fewer patients in the active group needed rescue therapy [ 75 ].